BACKGROUND AND OBJECTIVES We sought to evaluate the effect of the early use of ezetimibe/simvastatin (Vytorin®) on arterial healing and endothelialization after the implantation of a drug-eluting stent (DES) in a porcine model of coronary restenosis. MATERIALS AND METHODS A total of 20 pigs (40 coronary arteries) were randomly allocated to a pretreatment or no treatment group. The pretreatmen...

BACKGROUND In the RESOLUTE All Comers trial, the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus-eluting stent for the primary stent-related endpoint of target lesion failure (cardiac death, target vessel myocardial infarction, and ischaemia-driven target lesion revascularisation) at 1 year. However, data for long-term safety and efficacy from randomised studies o...

The aim of this study was to investigate the safety and efficacy biodegradable-polymer sirolimus-eluting stents (BP-SES) compared with durable-polymer everolimus-eluting (DP-EES) in patients ST-segment elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention (PCI) is an effective treatment for STEMI, long-term outcomes are determined by profile newest generation drug-...

Bioresorbable vascular scaffolds (BVS) demonstrate favourable outcomes in patients with stable coronary disease with simple de novo coronary lesions1,2 and are considered the “fourth revolution” in percutaneous coronary intervention (PCI) technology. BVS represent a promising alternative to drug-eluting stents (DES) while offering the same advantages. We present the first case of in-stent reste...

Over the past decade, the advent of drug-eluting stents (DES) has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for repeat revascularisation. A number of stents capable of delivering an anti-proliferative agent designed to prevent neointimal hyperplasia, the principal mechanism of restenosis after stent...

INTRODUCTION Drug-eluting stents (DES) have significantly decreased the need for repeat coronary revascularization but concerns remain regarding the safety of first and second generation DES. We compared the safety and efficacy of a biolimus-eluting stent (with biodegradable polymer) with an everolimus-eluting stent (with durable polymer) one. METHODS We performed a randomized trial to compar...

OBJECTIVES The aim of the current study was to compare everolimus-eluting stents (EES) with sirolimus-eluting stents (SES) in patients undergoing primary angioplasty. BACKGROUND Drug-eluting stents may offer benefits in terms of repeat revascularization. However, as shown for first-generation drug-eluting stents, they may be counterbalanced by a potential higher risk of stent thrombosis, espe...

Second-generation metallic drug-eluting stents (DES) have been widely recommended for percutaneous coronary intervention. One of the main drawbacks of these devices is the risk of late adverse events (ie, beyond 1 year), particularly repeat revascularization, which are partly related to the persistence of the metallic stents in the coronary artery wall. In this context, the bioresorbable vascul...

BACKGROUND The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. The safety and effectiveness of BVS through this critical 3-year period have not been characterized. METHODS We performed an individual-patient-data pooled meta-analysis of the 4 randomized ABSORB trials in which 3389 patients with coronary artery disease were rand...

n engl j med 355;19 www.nejm.org november 9, 2006 1952 including Medtronic’s Endeavor (coated with zotarolimus), Abbott’s Xience V (coated with everolimus), and Conor Medsystem’s CoStar (coated with paclitaxel); however, given the concerns about late stent thrombosis, the FDA could ask companies for longer-term data before considering newer stents for approval in the United States. How long tha...